Table 5.
Total number of adverse events with grading and presentation time in treated (ornithine phenylacetate) and placebo patients.
| Severity | Infusion (70) |
Follow up (53) |
Total (123) |
|||
|---|---|---|---|---|---|---|
| Placebo n (%) |
OP n (%) |
Placebo n (%) |
OP n (%) |
Placebo n (%) |
OP n (%) |
|
| 40 (100%) | 30 (100%) | 28 (100%) | 25 (100%) | 68 (100%) | 55 (100%) | |
| Mild | 29 (72.5%) | 21 (70%) | 22 (78.5%) | 12 (48%) | 51 (72.8%) | 33 (55.9%) |
| Moderate | 9 (22.5%) | 8 (26.6%) | 4 (14.2%) | 8 (32%) | 13 (18.5%) | 16 (27.1%) |
| Severe | 2 (5%) | 1 (3.3%) | 2 (7.1%) | 5 (20%) | 4 (5.7%) | 6 (10.1%) |
OP, ornithyne phenylactetate.